Can Ozturk | Gazi University (original) (raw)

Papers by Can Ozturk

Turkiye Klinikleri Journal of Medical Sciences, 2010

Matrix metalloproteinase (MMP) and vascular endothelial growth factor (VEGF) which are involved i... more Matrix metalloproteinase (MMP) and vascular endothelial growth factor (VEGF) which are involved in anjiogenesis and serum intercellular adhesion molecule (sICAM) which is a transmembranous protein from the immunoglobulin family play important role in tumor progression. The aim of this study was to analyze the association of serum levels of MMP-9, MMP-13, VEGF and sICAM with clinical parameters and survival in patients with non-small-cell lung cancer (NSCLC), and to determine whether these proteins might be useful tumor markers for lung cancer. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : In our study, serum levels of MMP-9, MMP-13, VEGF and sICAM were analysed in 72 patients with NSCLC patients (mean age: 60.03±10.86) and 46 healthy controls (mean age: 61.13 ± 14.71). The analysis was performed by enyzme-linked immunosorbent assay (ELISA). R Re es su ul lt ts s: : The median survival of all patients was 22 months. Serum levels of sICAM, VEGF and MMP-9 were increased in NSCLC patients (985 ± 489.4, 248.7±255.9, 5148.2±1996.2) compared with the healthy controls (300.5 ± 204.1, 182.1 ± 207.5, 2943.6 ± 851.7), whereas MMP-13 levels were not significantly different from healthy control group (0.46 ± 0.48, 0.53 ± 1.35) (p> 0.05). No statistically significant relationships were found between all investigated serum parameters and age, smoking, Eastern Cooperative Oncology Group performance status, or gender (p> 0.05). Additionally, there was no significant association between all serum parameters levels and survival in NSCLC patients (p> 0.05). C Co on nc cl lu us si io on n: : High levels of MMP-9, VEGF and sICAM were found in NSCLC patients, however there was no statistically significance in MMP-13 levels. Analysis of serum levels of MMP-9, VEGF and sICAM appears as a potential tumor marker. K Ke ey y W Wo or rd ds s: : Vascular endothelial growth factors; lung; matrix metalloproteinases; intercellular adhesion molecule-1 Ö ÖZ ZE ET T A Am ma aç ç: : Anjiogenezis içinde yer alan matriks metalloproteinaz (MMP) ile vasküler endotelyal büyüme faktörü (VEGF) ve immunglogulin ailesi içinde yer alan transmembranöz bir protein olan dolaşımdaki intersellüler adezyon molekülleri (sICAM) tümör progresyonunda önemli rol oynar. Bu çalışmanın amacı, küçük hücreli dışı akciğer kanserli (KHDAK) hastalarda tedavi öncesi ölçülen MMP-9, MMP-13, VEGF ve sICAM serum düzeyleri ile hastaların klinik parametreleri ve yaşam süreleri arasındaki ilişkiyi analiz etmektir. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: :

Reports of Practical Oncology & Radiotherapy, 2013

In the management of malignant pleural mesothelioma, radiotherapy has been used for the purpose o... more In the management of malignant pleural mesothelioma, radiotherapy has been used for the purpose of prophylaxis to reduce the incidence of recurrence at surgical insertion sites or palliate the symptoms. The purpose of the study was to evaluate the techniques and effectiveness of radiotherapy in malignant pleural mesothelioma. Forty-four (18 female, 26 male) patients diagnosed with malignant pleural mesothelioma were retrospectively evaluated. All patients had surgery or thoracoscopic biopsy for diagnosis, staging or treatment and all received palliative or prophylactic radiotherapy. Fifty-seven percent of the patients received chemotherapy. Prophylactic radiation was applied to 27 patients with 4-15 MeV electron energies. The median radiotherapy dose was 30 Gy with 3 Gy daily fraction dose. During treatment, 12 patients had grade 1 erythema according to the RTOG scale. In 3 (12%) patients, a local failure at treatment field was observed. Palliative radiotherapy was applied to 17 patients for pain palliation. The median radiation dose was 40 Gy with 2 Gy daily fraction dose by using 6-18 MV photon and/or 4-12 MeV electron energies. Two patients had grade 1 erythema and one patient had grade 2 odynophagy according to the RTOG scale. For 10 (59%) patients, palliation of chest pain was delivered. No late toxicity was observed for all cases. Our experience showed that prophylactic and palliative radiotherapy are effective and safe therapy modalities in malignant pleural mesothelioma in preventing seeding metastasis at intervention sites or relieving pain. Prospective randomized studies are still needed to determine the benefits of radiotherapy application and to indicate optimum dose schemes.

Clinical Nuclear Medicine, 1988

The authors report a patient with alveolar microlithiasis who was treated for miliary tuberculosi... more The authors report a patient with alveolar microlithiasis who was treated for miliary tuberculosis eight years earlier and whose Tc-99m MDP scan revealed absent lung uptake. Diagnosis was established by bronchoalveolar lavage. Both the roentgenogram and computed tomography of the chest confirmed alveolar microlithiasis.

Respirology, 2005

Objective: Cisplatin-gemcitabine (PG) and cisplatin-etoposide (PE) combinations are active regim... more Objective: Cisplatin-gemcitabine (PG) and cisplatin-etoposide (PE) combinations are active regimens for non-small cell lung cancer (NSCLC). The present study aimed to compare PG with PE in the treatment of patients with stage IIIB and IV NSCLC.Methodology: We conducted a prospective, multicentre trial. A total of 166 patients were enrolled into the study and received either gemcitabine (1000 mg/m2) on days 1, 8 and 15 plus cisplatin (80 mg/m2) on day 2 every 4 weeks, or etoposide (100 mg/m2) on days 1, 2 and 3 plus cisplatin (80 mg/m2) on day 1 every 3 weeks.Results: The overall response rate was superior in the PG group (54.8%vs 39.0%, P = 0.045). There was no significant difference in survival between the two groups, with respective median and 1-year survival of 38 weeks and 33.3% for the PG group, and 34 weeks and 23.2% for the PE group. There was also no statistical difference for time to progression between the two groups. Neutropenia and thrombocytopenia were seen more frequently in the PG group (grade 3 neutropenia, 33.3%vs 15.9%, P = 0.012; grade 3 thrombocytopenia, 27.4%vs 3.7%, P < 0.001 and grade 4 thrombocytopenia, 10.7%vs 1.2%, P = 0.018).Conclusion: PG is an active chemotherapy regimen and has a better response rate than PE in advanced NSCLC, although there was no difference in time to progression and overall survival. A higher incidence of haematological toxicity was seen with PG than with PE.

Mycoses, 2004

In the present study, we present a patient with invasive pulmonary aspergillosis caused by Asperg... more In the present study, we present a patient with invasive pulmonary aspergillosis caused by Aspergillus fumigatus diagnosed by polymerase chain reaction (PCR) technique on blood and bronchoalveolar lavage fluid samples of the patient. The value of PCR in the diagnosis of aspergillosis is discussed.

Lung Cancer, 2005

Environmentally exposed erionite is a potent and unique inducer of malignant pleural mesothelioma... more Environmentally exposed erionite is a potent and unique inducer of malignant pleural mesothelioma (MPM) in Central Anatolia in Turkey. Previous studies have shown that erionite induced MPM has different biological behavior than asbestos induced MPM. Although impaired apoptosis has been implicated in tumor biology, the relationship between the type of environmental exposure and apoptosis has not yet been evaluated in MPM. The purpose of this study was to determine the expression of apoptosis regulating proteins and their prognostic significance in erionite and asbestos induced MPM. Thirty-five patients with MPM (16 erionite and 19 asbestos induced), and 17 patients with adenocarcinoma were comparatively evaluated. Expression of Bcl-2, Bax, Fas and Fas Ligand, were assessed by immunohistochemistry. Bcl-2 and Fas did not stain in almost all specimens. The staining extension of Bax was 13.75 ± 19.27%, 5.89 ± 14.51% and 7.38 ± 14.53% for erionite and asbestos induced MPM and adenocarcinoma, respectively (p = 0.566). The staining extension of Fas Ligand was 26.87 ± 31.87%, 46.10 ± 37.30% and 26.47 ± 23.23% for erionite and asbestos induced MPM, and adenocarcinoma, respectively (p = 0.123). Bax negative patients in erionite group had longer survival than Bax positive patients (18 months versus 14 months) (p = 0.06). Fas Ligand positive patients showed statistically better survival than Fas Ligand negative patients in all MPM group (15 months versus 12 months) (p = 0.05). Although all proteins expressed in similar extension in all samples, Bax staining displayed an inverse relation with survival in erionite group. This may implicate a difference in Bax functioning in erionite induced MPM. However, Fas Ligand may be functionally intact to reduce tumor survival.

Lung Cancer, 2005

tumor coils, presumably due to immunoed~]ng of HLA molecules or tumor antigens Interestingly. thi... more tumor coils, presumably due to immunoed~]ng of HLA molecules or tumor antigens Interestingly. this patient had a clinical and radiograpi'tc response to tTeatment Moreover. of the two patients that are HLA-A2 positive, tetTemer analysis of PBMCs demonstrated low levels of antigen-specific CD8 calls to SV40 large T-antigen and survivin in one patient Conduslons: Instillation of adenoviral vector into the pleura/ space results in IFN-I~ expression Western blot analysis and chromium release assays suggest that Ad IFN-I~ tTeatment of at least one patient resulted in not oniy the development of an immune response to a now antigen, but cytotexic activity Further analyses are being performed to confrm Izansgone expression and to ascart~n whether specific antigen responses and funotlonal cytctexic effects are generated in additional patients relieving Ad. IFN 13 treatment.

Turkiye Klinikleri Journal of Medical Sciences, 2010

Matrix metalloproteinase (MMP) and vascular endothelial growth factor (VEGF) which are involved i... more Matrix metalloproteinase (MMP) and vascular endothelial growth factor (VEGF) which are involved in anjiogenesis and serum intercellular adhesion molecule (sICAM) which is a transmembranous protein from the immunoglobulin family play important role in tumor progression. The aim of this study was to analyze the association of serum levels of MMP-9, MMP-13, VEGF and sICAM with clinical parameters and survival in patients with non-small-cell lung cancer (NSCLC), and to determine whether these proteins might be useful tumor markers for lung cancer. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : In our study, serum levels of MMP-9, MMP-13, VEGF and sICAM were analysed in 72 patients with NSCLC patients (mean age: 60.03±10.86) and 46 healthy controls (mean age: 61.13 ± 14.71). The analysis was performed by enyzme-linked immunosorbent assay (ELISA). R Re es su ul lt ts s: : The median survival of all patients was 22 months. Serum levels of sICAM, VEGF and MMP-9 were increased in NSCLC patients (985 ± 489.4, 248.7±255.9, 5148.2±1996.2) compared with the healthy controls (300.5 ± 204.1, 182.1 ± 207.5, 2943.6 ± 851.7), whereas MMP-13 levels were not significantly different from healthy control group (0.46 ± 0.48, 0.53 ± 1.35) (p> 0.05). No statistically significant relationships were found between all investigated serum parameters and age, smoking, Eastern Cooperative Oncology Group performance status, or gender (p> 0.05). Additionally, there was no significant association between all serum parameters levels and survival in NSCLC patients (p> 0.05). C Co on nc cl lu us si io on n: : High levels of MMP-9, VEGF and sICAM were found in NSCLC patients, however there was no statistically significance in MMP-13 levels. Analysis of serum levels of MMP-9, VEGF and sICAM appears as a potential tumor marker. K Ke ey y W Wo or rd ds s: : Vascular endothelial growth factors; lung; matrix metalloproteinases; intercellular adhesion molecule-1 Ö ÖZ ZE ET T A Am ma aç ç: : Anjiogenezis içinde yer alan matriks metalloproteinaz (MMP) ile vasküler endotelyal büyüme faktörü (VEGF) ve immunglogulin ailesi içinde yer alan transmembranöz bir protein olan dolaşımdaki intersellüler adezyon molekülleri (sICAM) tümör progresyonunda önemli rol oynar. Bu çalışmanın amacı, küçük hücreli dışı akciğer kanserli (KHDAK) hastalarda tedavi öncesi ölçülen MMP-9, MMP-13, VEGF ve sICAM serum düzeyleri ile hastaların klinik parametreleri ve yaşam süreleri arasındaki ilişkiyi analiz etmektir. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: :

Reports of Practical Oncology & Radiotherapy, 2013

In the management of malignant pleural mesothelioma, radiotherapy has been used for the purpose o... more In the management of malignant pleural mesothelioma, radiotherapy has been used for the purpose of prophylaxis to reduce the incidence of recurrence at surgical insertion sites or palliate the symptoms. The purpose of the study was to evaluate the techniques and effectiveness of radiotherapy in malignant pleural mesothelioma. Forty-four (18 female, 26 male) patients diagnosed with malignant pleural mesothelioma were retrospectively evaluated. All patients had surgery or thoracoscopic biopsy for diagnosis, staging or treatment and all received palliative or prophylactic radiotherapy. Fifty-seven percent of the patients received chemotherapy. Prophylactic radiation was applied to 27 patients with 4-15 MeV electron energies. The median radiotherapy dose was 30 Gy with 3 Gy daily fraction dose. During treatment, 12 patients had grade 1 erythema according to the RTOG scale. In 3 (12%) patients, a local failure at treatment field was observed. Palliative radiotherapy was applied to 17 patients for pain palliation. The median radiation dose was 40 Gy with 2 Gy daily fraction dose by using 6-18 MV photon and/or 4-12 MeV electron energies. Two patients had grade 1 erythema and one patient had grade 2 odynophagy according to the RTOG scale. For 10 (59%) patients, palliation of chest pain was delivered. No late toxicity was observed for all cases. Our experience showed that prophylactic and palliative radiotherapy are effective and safe therapy modalities in malignant pleural mesothelioma in preventing seeding metastasis at intervention sites or relieving pain. Prospective randomized studies are still needed to determine the benefits of radiotherapy application and to indicate optimum dose schemes.

Clinical Nuclear Medicine, 1988

The authors report a patient with alveolar microlithiasis who was treated for miliary tuberculosi... more The authors report a patient with alveolar microlithiasis who was treated for miliary tuberculosis eight years earlier and whose Tc-99m MDP scan revealed absent lung uptake. Diagnosis was established by bronchoalveolar lavage. Both the roentgenogram and computed tomography of the chest confirmed alveolar microlithiasis.

Respirology, 2005

Objective: Cisplatin-gemcitabine (PG) and cisplatin-etoposide (PE) combinations are active regim... more Objective: Cisplatin-gemcitabine (PG) and cisplatin-etoposide (PE) combinations are active regimens for non-small cell lung cancer (NSCLC). The present study aimed to compare PG with PE in the treatment of patients with stage IIIB and IV NSCLC.Methodology: We conducted a prospective, multicentre trial. A total of 166 patients were enrolled into the study and received either gemcitabine (1000 mg/m2) on days 1, 8 and 15 plus cisplatin (80 mg/m2) on day 2 every 4 weeks, or etoposide (100 mg/m2) on days 1, 2 and 3 plus cisplatin (80 mg/m2) on day 1 every 3 weeks.Results: The overall response rate was superior in the PG group (54.8%vs 39.0%, P = 0.045). There was no significant difference in survival between the two groups, with respective median and 1-year survival of 38 weeks and 33.3% for the PG group, and 34 weeks and 23.2% for the PE group. There was also no statistical difference for time to progression between the two groups. Neutropenia and thrombocytopenia were seen more frequently in the PG group (grade 3 neutropenia, 33.3%vs 15.9%, P = 0.012; grade 3 thrombocytopenia, 27.4%vs 3.7%, P < 0.001 and grade 4 thrombocytopenia, 10.7%vs 1.2%, P = 0.018).Conclusion: PG is an active chemotherapy regimen and has a better response rate than PE in advanced NSCLC, although there was no difference in time to progression and overall survival. A higher incidence of haematological toxicity was seen with PG than with PE.

Mycoses, 2004

In the present study, we present a patient with invasive pulmonary aspergillosis caused by Asperg... more In the present study, we present a patient with invasive pulmonary aspergillosis caused by Aspergillus fumigatus diagnosed by polymerase chain reaction (PCR) technique on blood and bronchoalveolar lavage fluid samples of the patient. The value of PCR in the diagnosis of aspergillosis is discussed.

Lung Cancer, 2005

Environmentally exposed erionite is a potent and unique inducer of malignant pleural mesothelioma... more Environmentally exposed erionite is a potent and unique inducer of malignant pleural mesothelioma (MPM) in Central Anatolia in Turkey. Previous studies have shown that erionite induced MPM has different biological behavior than asbestos induced MPM. Although impaired apoptosis has been implicated in tumor biology, the relationship between the type of environmental exposure and apoptosis has not yet been evaluated in MPM. The purpose of this study was to determine the expression of apoptosis regulating proteins and their prognostic significance in erionite and asbestos induced MPM. Thirty-five patients with MPM (16 erionite and 19 asbestos induced), and 17 patients with adenocarcinoma were comparatively evaluated. Expression of Bcl-2, Bax, Fas and Fas Ligand, were assessed by immunohistochemistry. Bcl-2 and Fas did not stain in almost all specimens. The staining extension of Bax was 13.75 ± 19.27%, 5.89 ± 14.51% and 7.38 ± 14.53% for erionite and asbestos induced MPM and adenocarcinoma, respectively (p = 0.566). The staining extension of Fas Ligand was 26.87 ± 31.87%, 46.10 ± 37.30% and 26.47 ± 23.23% for erionite and asbestos induced MPM, and adenocarcinoma, respectively (p = 0.123). Bax negative patients in erionite group had longer survival than Bax positive patients (18 months versus 14 months) (p = 0.06). Fas Ligand positive patients showed statistically better survival than Fas Ligand negative patients in all MPM group (15 months versus 12 months) (p = 0.05). Although all proteins expressed in similar extension in all samples, Bax staining displayed an inverse relation with survival in erionite group. This may implicate a difference in Bax functioning in erionite induced MPM. However, Fas Ligand may be functionally intact to reduce tumor survival.

Lung Cancer, 2005

tumor coils, presumably due to immunoed~]ng of HLA molecules or tumor antigens Interestingly. thi... more tumor coils, presumably due to immunoed~]ng of HLA molecules or tumor antigens Interestingly. this patient had a clinical and radiograpi'tc response to tTeatment Moreover. of the two patients that are HLA-A2 positive, tetTemer analysis of PBMCs demonstrated low levels of antigen-specific CD8 calls to SV40 large T-antigen and survivin in one patient Conduslons: Instillation of adenoviral vector into the pleura/ space results in IFN-I~ expression Western blot analysis and chromium release assays suggest that Ad IFN-I~ tTeatment of at least one patient resulted in not oniy the development of an immune response to a now antigen, but cytotexic activity Further analyses are being performed to confrm Izansgone expression and to ascart~n whether specific antigen responses and funotlonal cytctexic effects are generated in additional patients relieving Ad. IFN 13 treatment.